small cell lung carcinoma


Summary: A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA).

Top Publications

  1. Sadava D, Kane S. The effect of brassinolide, a plant steroid hormone, on drug resistant small-cell lung carcinoma cells. Biochem Biophys Res Commun. 2017;493:783-787 pubmed publisher
    ..Taken together, these data indicate that EB, a natural product with widespread occurrence in plants, is pharmacologically active in both drug-sensitive and drug-resistant SCLC cells and acts through the Wnt signaling pathway. ..
  2. Xu L, Fu Y, Li Y, Han X. Cisplatin induces expression of drug resistance-related genes through c-jun N-terminal kinase pathway in human lung cancer cells. Cancer Chemother Pharmacol. 2017;80:235-242 pubmed publisher
    ..Lung resistance protein (LRP) and anti-apoptotic genes (Bcl-2, Bcl-Xl, XIAP, Survivin) are involved in the process. The results reminded us of a novel therapy target for lung cancer treatment. ..
  3. Bahleda R, Grilley Olson J, Govindan R, Barlesi F, Greillier L, Perol M, et al. Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies. Br J Cancer. 2017;116:1505-1512 pubmed publisher
    ..4% for patients with SCLC (n=33), and 33.3% for patients with CDK-related tumour mutations (n=6). Roniciclib demonstrated an acceptable safety profile and moderate DCR in 3 days on/4 days off schedule. ..
  4. Weiss G, Waypa J, Blaydorn L, Coats J, McGahey K, Sangal A, et al. A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus). Br J Cancer. 2017;117:33-40 pubmed publisher
    ..Efficacy was observed in multiple tumour types and evaluation to determine if response and duration of response are more robust than what would be expected for chemotherapy or immunotherapy alone requires further validation. ..
  5. Cao C, Duan P, Zhang W, Li L, Qu F, Sun B, et al. Acute pancreatitis induced by etoposide-lobaplatin combination chemotherapy used for the treatment of lung cancer: A case report and literature review. Medicine (Baltimore). 2017;96:e7601 pubmed publisher
    ..We should raise awareness of the clinicians regarding DIP, thereby enabling its timely diagnosis and accurate treatment, as well as promoting the rational and safe use of drugs. ..
  6. Huang R, Wei Y, Hung R, Liu G, Su L, Zhang R, et al. Associated Links Among Smoking, Chronic Obstructive Pulmonary Disease, and Small Cell Lung Cancer: A Pooled Analysis in the International Lung Cancer Consortium. EBioMedicine. 2015;2:1677-85 pubmed
    ..Here we reveal the risks of smoking behaviors on SCLC which are partially mediated (up to 7.6%) through COPD. The findings warrant further experimental study to elucidate the mechanisms in this causal pathway. ..
  7. Lim J, Ibaseta A, Fischer M, Cancilla B, O Young G, Cristea S, et al. Intratumoural heterogeneity generated by Notch signalling promotes small-cell lung cancer. Nature. 2017;545:360-364 pubmed publisher
  8. Shin J, Brusselle G. Mechanistic links between COPD and lung cancer: a role of microRNA let?7?. Nat Rev Cancer. 2014;14:70 pubmed
  9. Jiang R, Dong X, Zhu W, Duan Q, Xue Y, Shen Y, et al. Combining PET/CT with serum tumor markers to improve the evaluation of histological type of suspicious lung cancers. PLoS ONE. 2017;12:e0184338 pubmed publisher
    ..05 for all). SUVmax and serum tumor markers show values in evaluating the histological types of suspicious lung cancers. When properly combined, the diagnostic efficiency can increase significantly. ..

More Information


  1. Lopez Sanchez L, Jurado Gámez B, Feu Collado N, Valverde A, Cañas A, Fernández Rueda J, et al. Exhaled breath condensate biomarkers for the early diagnosis of lung cancer using proteomics. Am J Physiol Lung Cell Mol Physiol. 2017;313:L664-L676 pubmed publisher
    ..Thus this study demonstrates that the proteomic analysis of EBC samples is an appropriated approach to develop biomarkers for the diagnosis of lung cancer. ..
  2. Yang Y, Sun N, Sun P, Zhang L. Clinical Characteristics and Prognosis of Elderly Small Cell Lung Cancer Patients Complicated with Hyponatremia: A Retrospective Analysis. Anticancer Res. 2017;37:4681-4686 pubmed
    ..It is important that the cause of the hyponatremia is diagnosed at an early stage and precise medical treatment is provided. ..
  3. Tripathi S, Fahrmann J, Celiktaş M, Aguilar M, Marini K, Jolly M, et al. MCAM Mediates Chemoresistance in Small-Cell Lung Cancer via the PI3K/AKT/SOX2 Signaling Pathway. Cancer Res. 2017;77:4414-4425 pubmed publisher
    ..Our results suggest that MCAM may serve as a novel therapeutic target to overcome chemoresistance in SCLC. Cancer Res; 77(16); 4414-25. ©2017 AACR. ..
  4. Naito Y, Tamiya A, Tamiya M, Kimura Y, Hamaguchi M, Saijo N, et al. Efficacy of nanoparticle albumin-bound paclitaxel regimens for relapsed small cell lung cancer: A retrospective analysis. Medicine (Baltimore). 2017;96:e7884 pubmed publisher
    ..Our results suggest that chemotherapy with nab-paclitaxel regimens for relapsed SCLC exhibits moderate clinical efficacy and is well-tolerated. Further clinical trials in relapsed SCLC patients are warranted. ..
  5. Li L, Song W, Yan X, Li A, Zhang X, Li W, et al. Friend leukemia virus integration 1 promotes tumorigenesis of small cell lung cancer cells by activating the miR-17-92 pathway. Oncotarget. 2017;8:41975-41987 pubmed publisher
    ..This study uncovers FLI1 as an important driving factor that promotes tumor growth in SCLC through the miR-17-92 pathway. FLI1 may serve as an attractive target for therapeutic intervention of SCLC. ..
  6. Taniguchi H, Yamada T, Takeuchi S, Arai S, Fukuda K, Sakamoto S, et al. Impact of MET inhibition on small-cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/MET pathway. Cancer Sci. 2017;108:1378-1385 pubmed publisher
    ..We suggest that it would be clinically valuable to further investigate HGF/MET-mediated signaling in SCLC cells. ..
  7. Messaritakis I, Politaki E, Kotsakis A, Dermitzaki E, Koinis F, Lagoudaki E, et al. Phenotypic characterization of circulating tumor cells in the peripheral blood of patients with small cell lung cancer. PLoS ONE. 2017;12:e0181211 pubmed publisher
  8. Ou S, Lee T, Young L, Fernandez Rocha M, Pavlick D, Schrock A, et al. Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?. Lung Cancer. 2017;106:110-114 pubmed publisher
    ..If clinically feasible, tissue-based re-biopsy allowing histological examination and CGP remains the gold standard to assess resistance mechanism(s) and to direct subsequent rational clinical care. ..
  9. Sørensen M, Pijls Johannesma M, Felip E. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 Suppl 5:v120-5 pubmed publisher
  10. Sundaresan V, Lin V, Liang F, Kaye F, Kawabata Iwakawa R, Shiraishi K, et al. Significantly mutated genes and regulatory pathways in SCLC-a meta-analysis. Cancer Genet. 2017;216-217:20-28 pubmed publisher
  11. Onishi H, Nakamura K, Nagai S, Yanai K, Yamasaki A, Kawamoto M, et al. Hedgehog Inhibition Upregulates TRK Expression to Antagonize Tumor Suppression in Small Cell Lung Cancer Cells. Anticancer Res. 2017;37:4987-4992 pubmed
    ..The human small cell lung carcinoma cell line, SBC-5, was used...
  12. Weiss G, Byron S, Aldrich J, Sangal A, Barilla H, Kiefer J, et al. A prospective pilot study of genome-wide exome and transcriptome profiling in patients with small cell lung cancer progressing after first-line therapy. PLoS ONE. 2017;12:e0179170 pubmed publisher
    ..Earlier access to NGS guided therapy, along with improved understanding of those SCLC patients likely to respond to immune-based therapies, should help to extend survival in these cases with poor outcomes. ..
  13. Haitham Abusara O, Freeman S, Aojula H. Pentapeptides for the treatment of small cell lung cancer: Optimisation by Nind-alkyl modification of the tryptophan side chain. Eur J Med Chem. 2017;137:221-232 pubmed publisher
    ..Concluding, the butyl substitutions offered the best perspective for high cytotoxicity, induction of apoptosis and metabolic compatibility thereby comprising an improved broad spectrum SP antagonist candidate for treatment of SCLC. ..
  14. Sabari J, Lok B, Laird J, Poirier J, Rudin C. Unravelling the biology of SCLC: implications for therapy. Nat Rev Clin Oncol. 2017;14:549-561 pubmed publisher
    ..Herein, we review the progress made in uncovering aspects of the biology of SCLC and its microenvironment that are defining new therapeutic strategies and offering renewed hope for patients. ..
  15. Rwigema J, Verma V, Lin L, Berman A, Levin W, Evans T, et al. Prospective study of proton-beam radiation therapy for limited-stage small cell lung cancer. Cancer. 2017;123:4244-4251 pubmed publisher
    ..In the first prospective registry study and largest analysis to date of PBT for LS-SCLC, PBT was found to be safe with a limited incidence of high-grade toxicities. Cancer 2017;123:4244-4251. © 2017 American Cancer Society. ..
  16. Alexander M, Chiaffarano J, Zhou F, Cangiarella J, Yee Chang M, Simsir A. Can p40 (Polyclonal) Replace p63 (Clone 4A4) in the Cytologic Diagnosis of Pulmonary Non-Small Cell Carcinoma?. Am J Clin Pathol. 2017;147:580-588 pubmed publisher
    ..Among metastatic ACAs from other sites (n = 14), more cases were positive for p40 than p63. Polyclonal p40 yields a level of false positivity in ACAs similar to p63, which is highest in effusions and is not limited to lung origin. ..
  17. Fruh M, De Ruysscher D, Popat S, Crino L, Peters S, Felip E. Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24 Suppl 6:vi99-105 pubmed publisher
  18. Weiskopf K, Jahchan N, Schnorr P, Cristea S, Ring A, Maute R, et al. CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. J Clin Invest. 2016;126:2610-20 pubmed publisher
    ..This approach could enable personalized immunotherapeutic regimens in patients with SCLC and other cancers. ..
  19. Chen X, Xu Y, Duan J, Li C, Sun H, Wang W. Correlation of iodine uptake and perfusion parameters between dual-energy CT imaging and first-pass dual-input perfusion CT in lung cancer. Medicine (Baltimore). 2017;96:e7479 pubmed publisher
    ..Preliminary results demonstrated that the iodine uptake relevant parameters derived from DE-CT significantly correlated with perfusion parameters derived from DI-PCT. ..
  20. Haruta Inoue Y, Kataoka Y, Nikaido J, Nakajima N. Histological transformation from non-small cell to small cell lung carcinoma. BMJ Case Rep. 2016;2016: pubmed publisher
  21. Asamura H. Identity, similarity, and difference between large cell neuroendocrine carcinoma and small cell carcinoma. J Thorac Oncol. 2011;6:1774; author reply 1776 pubmed publisher
  22. Barnes H, See K, BARNETT S, Manser R. Surgery for limited-stage small-cell lung cancer. Cochrane Database Syst Rev. 2017;4:CD011917 pubmed publisher
  23. Miret M, Horvath Puho E, Déruaz Luyet A, Sørensen H, Ehrenstein V. Potential paraneoplastic syndromes and selected autoimmune conditions in patients with non-small cell lung cancer and small cell lung cancer: A population-based cohort study. PLoS ONE. 2017;12:e0181564 pubmed publisher
    ..These results provide context to discerning PNS from adverse effects of novel immunotherapies during the clinical course of NSCLC and SCLC. ..
  24. Bonifazi M, Sediari M, Ferretti M, Poidomani G, Tramacere I, Mei F, et al. The role of the pulmonologist in rapid on-site cytologic evaluation of transbronchial needle aspiration: a prospective study. Chest. 2014;145:60-65 pubmed publisher
    ..Training pulmonologists to have a basic knowledge of cytopathology could obviate most difficulties related to the involvement of cytopathologists in routine diagnostic activities and may reduce the costs of the procedure. ..
  25. Park S, Choi J, Moon S, Yoo J, Kim H, Ahn Y, et al. Prognostic value of volumetric metabolic parameters measured by [18F]fluorodeoxyglucose-positron emission tomography/computed tomography in patients with small cell lung cancer. Cancer Imaging. 2014;14:2 pubmed publisher
    ..However, it may be more useful in limited disease rather than in extensive disease. ..
  26. Yang C, Chan D, Speicher P, Gulack B, Tong B, Hartwig M, et al. Surgery Versus Optimal Medical Management for N1 Small Cell Lung Cancer. Ann Thorac Surg. 2017;103:1767-1772 pubmed publisher
    ..These results support the re-evaluation of the role of surgery in multimodality therapy for N1 SCLC in a clinical trial setting. ..
  27. Wang X, Zhang Y, Hu M, Wang R, Liu L, Qian K, et al. [Prognostic and Predictive Value of Thyroid Transcription Factor-1, CD56, P40 and Other Clinical Characteristics in Small Cell Lung Cancer Patients]. Zhongguo Fei Ai Za Zhi. 2017;20:522-527 pubmed publisher
    ..551?95%CI?2.133-5.914????????????OR=2.487?95%CI?1.793-3.451?????????????superior vena cava syndrome, SVCS??OR=2.394?95%CI?1.49-3.846??? ??????????TTF-1??????ECOG??????????SVCS????????TTF-1?CD56?P40???????????????????????. ..
  28. Szczepny A, Rogers S, Jayasekara W, Park K, McCloy R, Cochrane C, et al. The role of canonical and non-canonical Hedgehog signaling in tumor progression in a mouse model of small cell lung cancer. Oncogene. 2017;36:5544-5550 pubmed publisher
    ..These results provide strong support for an autocrine, ligand-dependent model of Hh signaling in SCLC pathogenesis, and reveal a novel role for non-canonical Hh signaling through the induction of chromosomal instability...
  29. El Zein R, Abdel Rahman S, Santee K, Yu R, Shete S. Identification of Small and Non-Small Cell Lung Cancer Markers in Peripheral Blood Using Cytokinesis-Blocked Micronucleus and Spectral Karyotyping Assays. Cytogenet Genome Res. 2017;152:122-131 pubmed publisher
    ..Given the high frequency of chromosome aberrations observed in SCLC, events such as reinsertion of the micronucleus and chromothripsis may be potential mechanisms for the genetic instability in these patients. ..
  30. Sharma S, Pourat J, Abdel Atti D, Carlin S, Piersigilli A, Bankovich A, et al. Noninvasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer. Cancer Res. 2017;77:3931-3941 pubmed publisher
    ..5 therapy in SCLC patient-derived xenograft models. Cancer Res; 77(14); 3931-41. ©2017 AACR. ..
  31. Kalemkerian G, Akerley W, Bogner P, Borghaei H, Chow L, Downey R, et al. Small cell lung cancer. J Natl Compr Canc Netw. 2013;11:78-98 pubmed
    ..Most cases of SCLC are attributable to cigarette smoking; therefore, smoking cessation should be strongly promoted. ..
  32. Guo S, Liang Y, Zhou Q. Complement and correction for meta-analysis of patients with extensive-stage small cell lung cancer managed with irinotecan/cisplatin versus etoposide/cisplatin as first-line chemotherapy. J Thorac Oncol. 2011;6:406-8; author reply 408 pubmed publisher
  33. Koinis F, Agelaki S, Karavassilis V, Kentepozidis N, Samantas E, Peroukidis S, et al. Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group. Br J Cancer. 2017;117:8-14 pubmed publisher
    ..Second-line treatment with pazopanib in platinum-sensitive SCLC is well tolerated and resulted in promising objective responses and disease control; CTC enumeration might serve as a reliable surrogate biomarker of response. ..
  34. Wang F, Lu J, Li S, Huo X, Liu X, Du X, et al. Application of Serum ELAVL4 (HuD) Antigen Assay for Small Cell Lung Cancer Diagnosis. Anticancer Res. 2017;37:4515-4522 pubmed
    ..The high titres of HuD in SCLC patients and preferable consistency suggested that HuD may serve as a potential diagnostic criterium for SCLC and may serve as a marker of disease progression. ..
  35. Dean R, Subedi R, Gill D, Nat A. Consideration of alternative causes of lactic acidosis: Thiamine deficiency in malignancy. Am J Emerg Med. 2017;35:1214.e5-1214.e6 pubmed publisher
    ..The purpose of this paper is to bring awareness to the clinician to consider other causes of lactic acidosis when evaluating a patient. ..
  36. Shao W, Wang X, Liu D. [Recent Advances and Future Strategies for Small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi. 2017;20:421-426 pubmed publisher
    ..This review will focus on current therapy and future research direction of SCLC. ???????????????????????????????????????????????????????????????????????????????????????????????????????. ..
  37. Sen T, Tong P, Stewart C, Cristea S, Valliani A, Shames D, et al. CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib. Cancer Res. 2017;77:3870-3884 pubmed publisher
    ..Our findings provide a preclinical proof of concept supporting the initiation of a clinical efficacy trial in patients with platinum-sensitive or platinum-resistant relapsed SCLC. Cancer Res; 77(14); 3870-84. ©2017 AACR. ..
  38. Redmond K, Hales R, Anderson Keightly H, Zhou X, Kummerlowe M, Sair H, et al. Prospective Study of Hippocampal-Sparing Prophylactic Cranial Irradiation in Limited-Stage Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2017;98:603-611 pubmed publisher
    ..These data strongly support continued enrollment on ongoing cooperative group randomized trials. Clinical Trials registration number: NCT01797159. ..
  39. Gao H, Niu Y, Li M, Fang S, Guo L. Identification of DJ-1 as a contributor to multidrug resistance in human small-cell lung cancer using proteomic analysis. Int J Exp Pathol. 2017;98:67-74 pubmed publisher
    ..These findings suggest DJ-1 may serve as a potential biomarker for chemoresistance and prognostic factor for patients with SCLC. ..
  40. Loiselle J, Roy J, Sutherland L. RBM10 promotes transformation-associated processes in small cell lung cancer and is directly regulated by RBM5. PLoS ONE. 2017;12:e0180258 pubmed publisher
    ..Measurement of both RBM10 and RBM5 expression in clinical samples may therefore hold prognostic and/or potentially predictive value. ..
  41. Chen Y, Peng Y, Yao M, Teng J, Ni D, Zhu Z, et al. Cisplatin and photodynamic therapy exert synergistic inhibitory effects on small-cell lung cancer cell viability and xenograft tumor growth. Biochem Biophys Res Commun. 2017;487:567-572 pubmed publisher
    ..Taken together, our findings suggest that low dose cisplatin combination with PDT can be an effective therapeutic modality in the treatment of SCLC patients. ..
  42. Zhou T, Zhan J, Fang W, Zhao Y, Yang Y, Hou X, et al. Serum low-density lipoprotein and low-density lipoprotein expression level at diagnosis are favorable prognostic factors in patients with small-cell lung cancer (SCLC). BMC Cancer. 2017;17:269 pubmed publisher
    ..Patients with high LDL or LDLR expression level may benefit from treatment that modulates lipoprotein combined with platinum-based chemotherapy. ..
  43. Peake M. Deprivation, distance and death in lung cancer. Thorax. 2015;70:108-9 pubmed publisher
  44. Aktan M, Koc M, Kanyilmaz G, Yavuz B. Prognostic value of pre-treatment 18F-FDG-PET uptake in small-cell lung cancer. Ann Nucl Med. 2017;31:462-468 pubmed publisher
    ..Patients with a higher pre-treatment FDG uptake may be considered at increased risk of failure and may benefit from more aggressive treatment approaches. ..
  45. Hu W, Wei H, Li K, Li P, Lin J, Feng R. Downregulation of USP32 inhibits cell proliferation, migration and invasion in human small cell lung cancer. Cell Prolif. 2017;50: pubmed publisher
    ..Our results suggest for the first time that USP32 is important for SCLC progression and might be a potential target for molecular therapy of SCLC. ..
  46. Travis W. Lung tumours with neuroendocrine differentiation. Eur J Cancer. 2009;45 Suppl 1:251-66 pubmed publisher
  47. Yang X, Tang C, Luo H, Wang H, Zhou X. Shp2 confers cisplatin resistance in small cell lung cancer via an AKT-mediated increase in CA916798. Oncotarget. 2017;8:23664-23674 pubmed publisher
    ..Therefore, Shp2 and CA916798 may be promising biomarkers for predicting resistance to chemotherapy and may function as targets for enhancing treatments. ..
  48. Kenz S, Haas C, Werth S, Bohnet S, Brabant G. High sensitivity to tolvaptan in paraneoplastic syndrome of inappropriate ADH secretion (SIADH). Ann Oncol. 2011;22:2696 pubmed publisher
  49. Li Z, Wang Y, Kong L, Yue Z, Ma Y, Chen X. Expression of ADAM12 is regulated by E2F1 in small cell lung cancer. Oncol Rep. 2015;34:3231-7 pubmed
    ..Thus, the present findings support the conclusion that the E2F1 transcription factor regulates the expression of ADAM12 by binding differential cis-acting elements. ..
  50. Jalal S, Lavin P, Lo G, Lebel F, Einhorn L. Carboplatin and Etoposide With or Without Palifosfamide in Untreated Extensive-Stage Small-Cell Lung Cancer: A Multicenter, Adaptive, Randomized Phase III Study (MATISSE). J Clin Oncol. 2017;35:2619-2623 pubmed publisher
    ..Median overall survival was similar between both arms with 10.03 months on PaCE and 10.37 months on CE ( P = .096). Conclusion The addition of palifosfamide to CE failed to improve survival in ES SCLC. ..
  51. Takagi S, Ishikawa Y, Mizutani A, Iwasaki S, Matsumoto S, Kamada Y, et al. LSD1 Inhibitor T-3775440 Inhibits SCLC Cell Proliferation by Disrupting LSD1 Interactions with SNAG Domain Proteins INSM1 and GFI1B. Cancer Res. 2017;77:4652-4662 pubmed publisher
    ..Targeting these critical interactions with LSD1 inhibitors offers a novel rational strategy to therapeutically manage SCLC. Cancer Res; 77(17); 4652-62. ©2017 AACR. ..
  52. Morimura O, Minami T, Kijima T, Koyama S, Otsuka T, Kinehara Y, et al. Trastuzumab emtansine suppresses the growth of HER2-positive small-cell lung cancer in preclinical models. Biochem Biophys Res Commun. 2017;488:596-602 pubmed publisher
    ..Collectively, T-DM1 will be a promising option for overcoming trastuzumab-resistance in HER2-upregulated SCLC. ..
  53. Udyavar A, Hoeksema M, Clark J, Zou Y, Tang Z, Li Z, et al. Co-expression network analysis identifies Spleen Tyrosine Kinase (SYK) as a candidate oncogenic driver in a subset of small-cell lung cancer. BMC Syst Biol. 2013;7 Suppl 5:S1 pubmed publisher
    ..This strategy is especially useful in cancer types where no actionable mutations have emerged. ..
  54. Turk M, Yildirim F, Yurdakul A, Ozturk C. Hospitalization costs of lung cancer diagnosis in Turkey: Is there a difference between histological types and stages?. Tuberk Toraks. 2016;64:263-268 pubmed
    ..05). There is no significant difference between costs related to diagnosis of different lung cancer types and stages in patients hospitalized in a university hospital. ..
  55. Roca E, Gurizzan C, Amoroso V, Vermi W, Ferrari V, Berruti A. Outcome of patients with lung adenocarcinoma with transformation to small-cell lung cancer following tyrosine kinase inhibitors treatment: A systematic review and pooled analysis. Cancer Treat Rev. 2017;59:117-122 pubmed publisher
    ..The prognosis after SCLC diagnosis is poor and current treatment strategies derived from primary SCLC seem to be largely inefficacious. New therapies are needed in the management of transformed SCLC. ..
  56. Baize N, Monnet I, Greillier L, Quere G, Kerjouan M, Janicot H, et al. Second-line treatments of small-cell lung cancers. Expert Rev Anticancer Ther. 2017;17:1033-1043 pubmed publisher
    ..The inclusion of SCLC patients relapsing after platin-doublet induction in well-designed clinical trials remains a major challenge...
  57. Kim S, Kim M, Kim Y, Chang H, Kim J, Lee J, et al. Paclitaxel as third-line chemotherapy for small cell lung cancer failing both etoposide- and camptothecin-based chemotherapy. Medicine (Baltimore). 2017;96:e8176 pubmed publisher
    ..Paclitaxel-based chemotherapy showed modest activity in SCLC patients refractory to both etoposide- and camptothecin-based chemotherapy. PS and presence of liver metastasis were predictive of survival after paclitaxel chemotherapy...
  58. Ross J, Wang K, Elkadi O, Tarasen A, Foulke L, Sheehan C, et al. Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer. J Clin Pathol. 2014;67:772-6 pubmed
    ..Given the limited treatment options and poor prognosis of patients with SCLC, comprehensive genomic profiling has the potential to identify new treatment paradigms and meet an unmet clinical need for this disease. ..
  59. Redig A, Janne P. Basket trials and the evolution of clinical trial design in an era of genomic medicine. J Clin Oncol. 2015;33:975-7 pubmed publisher
  60. Jiang W, Zhang W, Wu L, Liu L, Men Y, Wang J, et al. MicroRNA-Related Polymorphisms in PI3K/Akt/mTOR Pathway Genes Are Predictive of Limited-Disease Small Cell Lung Cancer Treatment Outcomes. Biomed Res Int. 2017;2017:6501385 pubmed publisher
  61. Başara Akın I, Altay C, Balci P. Imaging findings of pseudomesothelioma cases resulting from two different primary tumours. Tuberk Toraks. 2016;64:253-255 pubmed
    ..Herein we report two cases of pseudomesothelioma resulting from small cell carcinoma and RCC. ..
  62. Hassan W, Takebayashi S, Abdalla M, Fujino K, Kudoh S, Motooka Y, et al. Correlation between histone acetylation and expression of Notch1 in human lung carcinoma and its possible role in combined small-cell lung carcinoma. Lab Invest. 2017;97:913-921 pubmed publisher
  63. Hamilton G, Rath B. Mesenchymal-Epithelial Transition and Circulating Tumor Cells in Small Cell Lung Cancer. Adv Exp Med Biol. 2017;994:229-245 pubmed publisher
  64. Gardner E, Poirier J, Rudin C. Histone Code Aberrancies in Small Cell Lung Cancer. J Thorac Oncol. 2017;12:599-601 pubmed publisher
  65. Du W, Xu X, Niu Q, Zhang X, Wei Y, Wang Z, et al. Spi-B-Mediated Silencing of Claudin-2 Promotes Early Dissemination of Lung Cancer Cells from Primary Tumors. Cancer Res. 2017;77:4809-4822 pubmed publisher
    ..These data suggest that Spi-B participates in mesenchymal invasion, linking epithelial cancer metastasis with a lymphatic transcriptional program. Cancer Res; 77(18); 4809-22. ©2017 AACR. ..
  66. Li W, Xie S, Tse L, Lagergren J. Digitalis use and lung cancer risk by histological type in men. Int J Cancer. 2017;141:1981-1986 pubmed publisher
    ..39-0.79) and squamous cell carcinoma (HR 0.40, 95% CI 0.19-0.87). This large and population-based study suggests decreased risks of lung cancer overall and squamous cell carcinoma associated with long-term use of digitalis in men. ..
  67. Barh D, Jain N, Tiwari S, Field J, Padin Iruegas E, Ruibal A, et al. A novel in silico reverse-transcriptomics-based identification and blood-based validation of a panel of sub-type specific biomarkers in lung cancer. BMC Genomics. 2013;14 Suppl 6:S5 pubmed publisher
    ..The strategy developed in this work is applicable to any other cancer or disease and can assist in the identification of potential biomarkers. ..